"Enoxaparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)
| Descriptor ID |
D017984
|
| MeSH Number(s) |
D09.698.373.400.300.200
|
| Concept/Terms |
PK-10,169- PK-10,169
- PK 10,169
- PK10,169
- PK-10169
- PK 10169
- PK10169
|
Below are MeSH descriptors whose meaning is more general than "Enoxaparin".
Below are MeSH descriptors whose meaning is more specific than "Enoxaparin".
This graph shows the total number of publications written about "Enoxaparin" by people in this website by year, and whether "Enoxaparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 4 | 0 | 4 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enoxaparin" by people in Profiles.
-
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
-
Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
-
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
-
Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience. Clin Neurol Neurosurg. 2021 08; 207:106792.
-
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.
-
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
-
Venous Thromboembolism Prophylaxis: Safe, but Still Provocative? Thromb Haemost. 2019 11; 119(11):1716-1718.
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
-
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164.